Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

C4X Discovery Holdings signs licensing agreement with Sanofi, shares jump

Stock Markets Apr 12, 2021 09:42
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.

By Samuel Indyk

Investing.com – C4X Discovery Holdings PLC (LON:C4XD), a UK-based pharmaceutical company, announced today that its subsidiary C4X Discovery Limited has signed an exclusive global licensing agreement with French pharmaceutical company Sanofi (PA:SASY) for its oral pre-clinical IL-17A inhibitor programme.

Financial terms

C4X will receive an upfront payment of €7mln from Sanofi, plus €11mln in pre-clinical payments. The company could also receive a further €407mln if certain development, regulatory and commercialisation milestones are met, meaning the total value of the deal is up to €414mln.

Treatment

The IL-17 family of cytokines are strong inducers of inflammation and are implicated in a variety of autoimmune diseases including psoriasis, psoriatic arthritis and ankylosing spondylitis. Under the license, Sanofi will develop and commercialise an oral therapy for the treatment of these inflammatory diseases.

“We are proud to be working with Sanofi to create much needed oral therapies in the underserved inflammatory disease space.,” said C4X Discovery CEO Clive Dix. “The Psoriasis market alone is estimated to be worth circa $24bln per annum by 2027, and when combined with Sanofi's development expertise our programme has the potential to address a number of indications.”

“This is the second significant agreement for a C4XD programme and marks a major milestone for the Company, not only validating the strength of our Drug Discovery expertise, but also our strategy to drive shareholder value through early-stage revenue generating deals.”

This is not the first deal with a major pharmaceutical signed by C4X. In 2018 the company signed a licensing agreement with Indivior PLC (LON:INDV) worth up to $294mln to help treat addiction. That drug is currently in a phase 1 clinical trial for treatment of opioid use disorder.

“With Indivior progressing our molecule for opioid addiction through a Phase I clinical trial and now our partnership with Sanofi driving potential next generation oral IL-17 therapies, we look forward with confidence to further develop our portfolio and deliver additional novel small molecule drug candidates tackling significant patient needs,” Dix added.

At 09:40BST, C4X shares were up 12.5% at 45.00p per share. Sanofi shares were unchanged at €85.12.

C4X Discovery Holdings signs licensing agreement with Sanofi, shares jump
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Ashraf Perwez
Ashraf Perwez Apr 12, 2021 11:16
Saved. See Saved Items.
This comment has already been saved in your Saved Items
india
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email